FOREX 3 minutes to read

AbbVie puckers up for Botox-maker

Michael O’Neill

FX Trader, Loonieviews.net

Summary:  Big pharma is hitting the headlines today after AbbVie Inc (ABBV: NYSE) puckered up, then ponied up $63.0 billion in cash and stock to acquire Botox-maker Allergan (AGN: NYSE).


Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each AGN share, making the deal worth $188.24/per AGN share. The combined companies are projected to generate $19.0 billion in operating cash flow with expected annual synergies and cost savings of $2.0 billion in year three. Closing is planned for early 2020, subject to regulatory and AGN shareholder approvals. AGN jumped 30%, and ABBV lost 10.17% at the New York open.

The news wasn’t enough for Wall Street to extend the June rally. The three major indices were modestly lower as of 14:00 GMT but are still up over 4.0% for the month. Mixed US data, which included a slightly softer Case-Shiller Home Price Index. (Actual 2.5% vs forecast 2.6%) was ignored.

Traders that believe the stock market rally was because of the Fed’s dovish shift and the prospect of two rate cuts before the end of the year, would be wrong. President Trump tweeted the real reason for the gains: “Stock Market is heading for one of the best months (June) in the history of our Country. Thank you Mr. President!”

USDCAD drifted lower, probing support in the 1.3130-50 zone. Prices are under pressure due to the surge in crude oil prices and from broad US dollar weakness. A surprising jump in Canadian Wholesale Sales in April (actual 1.7% m/m vs forecast 0.2%) added to the negative sentiment. 

FX markets remain cautious do the ongoing US/Iran tensions and ahead of news from the next round of China/US trade talks. Fed Chair Powell is speaking at lunchtime in New York but isn’t expected to deviate from his post-FOMC press conference remarks.
Chart:USDCAD 30 minute. Source: Saxo Bank.
Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)